US FDA expands approval for Avadel's sleep disorder drug

Avadel Pharmaceuticals

17/10/2024 14:51

Oct 17 - The U.S. Food and Drug Administration has
approved Avadel Pharmaceuticals'  AVDL.O  sleep disorder drug
for children aged 7 years and older, broadening its use and
heating up competition for widely used treatments from Jazz
Pharma. 
    Avadel said on Thursday the drug, called Lumryz, was now
approved to treat pediatric patients with sudden muscle weakness
called cataplexy or for excessive daytime sleepiness (EDS). It
was approved for adults in 2023. 
        
  

 (Reporting by Unnamalai L and Christy Santhosh in Bengaluru;
Editing by Devika Syamnath)
 ((Unnamalai.L@thomsonreuters.com;))